<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53919">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02404220</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-339-1560</org_study_id>
    <secondary_id>2015-002768-18</secondary_id>
    <nct_id>NCT02404220</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoid Leukemia (ALL)</brief_title>
  <official_title>A Phase 1b, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) With Vincristine and Dexamethasone in Adult Subjects With Relapsed or Refractory Acute Lymphoid Leukemia (ALL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, efficacy, tolerability, and pharmacokinetics of
      entospletinib (GS-9973) in combination with vincristine (VCR), and dexamethasone in adults
      with previously treated relapsed or refractory B-cell lineage acute lymphoid leukemia (ALL).

      This study consists of two parts: Dose Escalation and Dose Expansion. After 2 induction
      cycles during either parts of the study, participants may be put on maintenance for up to 36
      cycles if they have obtained clinical benefit from the treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2015</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of adverse events and laboratory abnormalities defined as dose limiting toxicities (DLTs)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>This composite endpoint will measure the safety profile of entospletinib.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall remission (CR or CRi) rate at end of induction</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Overall remission rate is defined as the proportion of participants who achieve a complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) at end of induction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete remission (CR) rate at end of induction</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Complete remission (CR) rate is defined as proportion of participants who achieve a complete remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and proportion of participants who receive post-treatment hematopoietic stem cell transplant (HSCT)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and proportion of participants who receive other post-treatment leukemia therapy</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial response (PR) rate at end of induction</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Partial response (PR) rate is defined as the proportion of participants who achieve a partial response of marrow or by imaging criteria for patients with extramedullary disease.
Imaging will not be performed for participants at sites in Germany.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response (CR, CRi, or PR) rate at end of induction</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Overall response (CR, CRi, or PR) rate is defined as the proportion of participants who achieve a complete remission (CR), complete remission with incomplete hematologic recovery (CRi) or partial response (PR) at end of induction.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Acute Lymphoid Leukemia</condition>
  <arm_group>
    <arm_group_label>Entospletinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation:
Lead-in (7 day): Entospletinib up to 400 mg twice daily
Cycle 1 and 2 (28 days each): Entospletinib up to 400 mg twice daily+ VCR up to 2 mg once weekly + CNS prophylaxis on Day 28 + dexamethasone 20 mg twice daily on days 8-11 and 22-25 (Cycle 1) and Days 1- 4 and 15-18 (Cycle 2)
Cycle 3 (up to 36 maintenance cycles): Entospletinib up to 400 mg twice daily + VCR up to 2 mg on Day 1+ dexamethasone 20 mg once daily on Days 1- 4 and 15-28 of each 28 day cycle
Dose Expansion:
Cycle 1 and 2 (28 days each): Entospletinib at the maximum tolerated dose (MTD) or recommended dose twice daily+ VCR up to 2 mg once weekly+ CNS prophylaxis on Day 28 +dexamethasone 20 mg on Days 8-11 and 22-25 (Cycle 1) and Days 1-4 and 15-18 (Cycle 2)
Cycle 3 (up to 36 maintenance cycles): Entospletinib at the MTD or recommended dose twice daily + VCR up to 2 mg on Day 1+ dexamethasone 20 mg once daily on Days 1- 4 and 15-18 of each 28-day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entospletinib</intervention_name>
    <description>Entospletinib tablet(s) administered orally</description>
    <arm_group_label>Entospletinib</arm_group_label>
    <other_name>GS-9973</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VCR</intervention_name>
    <description>Vincristine (VCR) administered intravenously</description>
    <arm_group_label>Entospletinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone tablet(s) administered orally</description>
    <arm_group_label>Entospletinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CNS Prophylaxis</intervention_name>
    <description>CNS prophylaxis per institutional standard</description>
    <arm_group_label>Entospletinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Adults with ALL in need of treatment

        Key Exclusion Criteria:

          -  Diagnosis of Burkitt's Leukemia, or lymphoid blast crisis of chronic myelogenous
             leukemia (CML)

          -  History of myelodysplastic syndrome or solid organ transplantation

          -  Prior allogeneic bone marrow progenitor cell transplant within 100 days or on active
             immunosuppression for graft versus host disease (GVHD) treatment or prophylaxis
             within 28 days prior to enrollment

        NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Study Team</last_name>
    <email>GS9973alerts@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Institute</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California San Diego (UCSD)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Bloomington</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford health systems</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bon Secour St. Francis Hospital</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of WA</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik mit Schwerpunkt Hamatologie/Onkologie</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Cologne</name>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik</name>
      <address>
        <city>Tubingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik I</name>
      <address>
        <city>Wurzburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 23, 2017</lastchanged_date>
  <firstreceived_date>March 2, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Syk inhibitor</keyword>
  <keyword>Blood malignancy</keyword>
  <keyword>Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
